Seelos Therapeutics to Participate in Two Investor Conferences in August

 
 

Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced it will participate in two investor conferences: the BTIG Virtual Biotechnology Conference on August 9 th and 10 th and the Canaccord Growth Conference on August 11 th and 12 th .

 
 

  (PRNewsfoto/Seelos Therapeutics, Inc.) 

 
 

Raj Mehra, Ph.D., Chairman and CEO, will present and host one on one meetings to provide a corporate update and overview of the company's programs, specifically Part 2 of the recently initiated registrational study of SLS-002 (intranasal racemic ketamine) in Adults with Major Depressive Disorder at imminent risk of suicide ( NCT04669665 ), the recently released in vivo data utilizing CRISPR-dCas9 gene therapy technology where a single dose of SLS-004 produced therapeutically desirable reductions in SNCA mRNA and SNCA protein expressions which are implicated as highly significant risk factors in Parkinson's disease, and the upcoming initiation of the SLS-005 Phase IIb/III pivotal study in amyotrophic lateral sclerosis (ALS) in the Healey ALS Platform Trial.

 

  BTIG Virtual Biotechnology Conference
Presentation: Tuesday, August 10   th from 11:00-11:25am ET  

 

  Canaccord Growth Conference
Presentation: Wednesday, August 11   th from 1:00-1:25pm ET  

 

If you or a loved one are having thoughts of suicide, please seek immediate medical help, go to your nearest emergency room, or call the   National Suicide Prevention Lifeline   at 1-800-273-8255.

 

  About Seelos Therapeutics  

 

Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system (CNS) disorders and other rare diseases. The Company's robust portfolio includes several late-stage clinical assets targeting indications including Acute Suicidal Ideation and Behavior (ASIB) in Major Depressive Disorder (MDD) or Post-Traumatic Stress Disorder (PTSD), amyotrophic lateral sclerosis (ALS), Sanfilippo syndrome, Parkinson's Disease, other psychiatric and movement disorders plus orphan diseases.

 

For more information, please visit our website: https://seelostherapeutics.com , the content of which is not incorporated herein by reference.

 

  Forward Looking Statements  

 

  Statements made in this press release, which are not historical in nature, constitute forward-looking statements for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. These statements include, among others, those regarding the anticipated Company discussion topics at the   BTIG Virtual Biotechnology Conference and the Canaccord Growth Conference, including proposed disclosure regarding Part 2 of Seelos' recently initiated registrational study of SLS-002 (intranasal racemic ketamine) in adults with major depressive disorder at imminent risk of suicide (    NCT04669665    ), the recently released in vivo data utilizing CRISPR-dCas9 gene therapy technology, and Seelos' proposed upcoming initiation of the SLS-005 Phase IIb/III pivotal study in amyotrophic lateral sclerosis (ALS) in the Healey ALS Platform Trial. These statements are based on Seelos' current expectations and beliefs and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Risks associated with Seelos' business include, but are not limited to, the risk of not successfully executing or continuing its preclinical and clinical studies and not gaining marketing approvals for its product candidates, the risk that prior clinical results may not be replicated in future studies and trials, the risks that clinical study results may not meet any or all endpoints of a clinical study and that any data generated from such studies may not support a regulatory submission or approval, the risks associated with the implementation of a new business strategy, the risks related to raising capital to fund its development plans and ongoing operations, risks related to Seelos' current stock price, risks related to the global impact of COVID-19, as well as other factors expressed in Seelos' periodic filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, even if subsequently made available by us on our website or otherwise. We do not undertake any obligation to update, amend or clarify these forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.  

 

  Contact Information  
Anthony Marciano  
Head of Corporate Communications
Seelos Therapeutics, Inc. (Nasdaq: SEEL)
300 Park Avenue
New York, NY 10022
(646) 293-2136
anthony.marciano@seelostx.com  
www.seelostherapeutics.com  
https://twitter.com/seelostx  
https://www.linkedin.com/company/seelos  

 
 
 

 Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/seelos-therapeutics-to-participate-in-two-investor-conferences-in-august-301332924.html  

 

SOURCE Seelos Therapeutics, Inc.

 
 

News Provided by PR Newswire via QuoteMedia

The Conversation (0)
Glowing mushrooms with colorful graphs in the background on a dark surface.

US Policy Momentum, Clinical Progress Fueling Psychedelics Market in 2025

When the US Food and Drug Administration (FDA) rejected Lykos Therapeutics’ new drug application for MDMA-assisted therapy last August, the initial disappointment cast a shadow over the psychedelics industry.

However, the sector is seeing a resurgence of optimism in 2025 on the back of various US developments.

“The psychedelic industry in 2025 will likely see significant advancements in clinical applications, particularly in treating PTSD, depression, and addiction, as research continues to validate their therapeutic potential,” Dr. Markus Ploesser, chief innovation officer at Open Mind Health, told Microdose in January.

Keep reading...Show less
AVECHO BIOTECHNOLOGY

Avecho and Sandoz enter Exclusive License and Development Agreement to Commercialise CBD for Insomnia in Australia

Avecho Biotechnology Limited (ASX: AVE) (“Avecho” or the “Company”) today announced it has signed an exclusive ten-year development and licensing agreement with Sandoz Group AG (“Sandoz”) for the commercial rights to Avecho’s Phase III cannabidiol (“CBD”) capsule for insomnia in Australia. Avecho retains the rights to commercialise the product in all other territories, with Sandoz granted a first right of refusal for these markets. Avecho’s CBD capsule aims to be the first pharmaceutical CBD product registered with the Therapeutic Goods Administration (“TGA”) as an over-the-counter medicine, which market forecasts predict could generate sales surpassing US$125M per annum in Australia2.

Keep reading...Show less

Compass Pathways to announce fourth quarter and year-end financial results on February 27th, 2025

 

  Compass management will host a conference call at 8:00 am ET (1:00pm UK)  

 

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Emyria Limited

Emyria and UWA in Partnership to Commercialise Novel Serotonin-Releasing Agents for Mental Health and Neurology

Emyria Limited (ASX: EMD) (“Emyria”, or the “Company”) has signed an exclusive licence agreement with UWA, granting worldwide rights to a rapidly growing portfolio of selective serotonin-releasing agents. (See Appendix for Key Commercial Terms). These novel compounds, realised through a UWA–Emyria research partnership launched in 2021,2 include potential next-generation treatments for mental health and neurological conditions such as PTSD and Parkinson’s disease.

Keep reading...Show less
Quantum Biopharm (CSE: QNTM)

Quantum BioPharma Files a US Federal Lawsuit Against CIBC World Markets, RBC Dominion Securities and Others, Seeking Damages in Excess of $700,000,000 USD, for Possible Stock Price Manipulation/Spoofing

Christian Attar Law Firm and Freedman Normand Friedland LLP, in conjunction with forensic investigators, have uncovered evidence of a potential multi-year market manipulation scheme that has caused substantial damages to the Company and its shareholders


Keep reading...Show less

Latest Press Releases

Related News

×